Previous close | 0.0500 |
Open | 0.7500 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 5.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0500 - 0.7500 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatiti
Aligos Therapeutics (ALGS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Aligos Therapeutics ( NASDAQ:ALGS ) First Quarter 2024 Results Key Financial Results Revenue: US$986.0k (down 64% from...